Middle East & Africa Pharmaceutical Excipients Market is expected to reach US$ 428.2 Million by 2034

According to The Insight Partners' research, the Middle East and Africa Pharmaceutical Excipients Market was valued at US$ 277.1 Million in 2025 and is expected to reach US$ 428.2 Million by 2034, registering a CAGR of 5.0% from 2026 to 2034.

Surging demand for generic medications and advanced formulations and increasing research and development efforts in novel excipients are among the critical factors attributed to drive the Middle East & Africa pharmaceutical excipients market.

The pharmaceutical excipients market is experiencing a surge in demand driven by the widespread adoption of generic medications. Governments of developing countries are focusing on reducing healthcare costs by boosting the production of generic drugs. This shift toward generics, which often replicate the active ingredients of branded drugs but rely heavily on excipients for stability, bioavailability, and manufacturability, has amplified the need for versatile inactive ingredients. Excipients comprise more than 90% of most generic drug formulations and play critical roles in ensuring product equivalence and patient safety, as highlighted by the International Pharmaceutical Excipients Council (IPEC). In the development of generic metformin hydrochloride tablets, variations in excipients such as microcrystalline cellulose and magnesium stearate have been shown to influence tablet hardness, dissolution rates, and quality attributes, underscoring the importance of precise formulation matching to achieve bioequivalence with the reference branded product. This demand extends to advanced formulations, where excipients enable innovative delivery systems, such as amorphous solid dispersions (ASDs), for poorly soluble drugs. In FDA-funded research, hypromellose acetate succinate emerged as a dominant carrier in spray-dried ASDs for generics, increasing drug loading from 5% to 30% with only 5% surfactant, impacting dissolution profiles and bioavailability. Similarly, hydroxypropyl methylcellulose (HPMC) matrices are pivotal in modified-release generics, where design-of-experiments studies revealed that excipient ratios affect scaling across strengths, ensuring consistent in vivo performance under dynamic gastrointestinal conditions. These advancements address complex challenges in generic development, such as food effects and polymorphic stability, fostering competition and accessibility.

Excipients have become an integral element in the manufacturing of tablets as these provide improved functionality in pharmaceuticals and aid in drug development and innovation, which help improve patent life at a lower cost. As generic approvals continue-with 59 first-time generics approved in fiscal year 2024-excipients remain indispensable for mitigating risks and supporting cost-effective therapies, benefiting public health through broader availability of affordable, high-quality medications.

On the contrary, stringent and complex regulatory frameworks hamper the growth of the Middle East & Africa pharmaceutical excipients market.

Middle East and Africa Pharmaceutical Excipients Market Segmentation Analysis:

• By Type, the Middle East and Africa Pharmaceutical Excipients Market is segmented into Bioresorbable Polymers and Lipids and Liposome Based Formulation, Oleochemicals, Sugars, Cellulose, Starches, Petrochemicals, Plant Proteins Polyols and Cyclodextrins, Inorganic Chemicals, and Others. The Cellulose segment is projected to expand at a CAGR of 4.9% during 2026 - 2034.
• By Oleochemicals For Type, the Middle East and Africa Pharmaceutical Excipients Market is segmented into Fatty Alcohols, Metal Stearates, Glycerin, and Other Oleochemicals. The Fatty Alcohols segment is projected to expand at a CAGR of 5.6% during 2026 - 2034.
• By Sugars For Type, the Middle East and Africa Pharmaceutical Excipients Market is segmented into Actual Sugars, Sugar Alcohols, and Artificial Sweeteners. The Actual Sugars segment is projected to expand at a CAGR of 4.2% during 2026 - 2034.
• By Cellulose For Type, the Middle East and Africa Pharmaceutical Excipients Market is segmented into Microcrystalline Cellulose, Cellulose Ethers, and Carboxymethylcellulose and Croscarmellose Sodium. The Microcrystalline Cellulose segment is projected to expand at a CAGR of 5.1% during 2026 - 2034.
• By Starches For Type, the Middle East and Africa Pharmaceutical Excipients Market is segmented into Modified Starches, Dried Starch, and Converted Starch and Pregelatinized Starch. The Modified Starches segment is projected to expand at a CAGR of 3.4% during 2026 - 2034.
• By Petrochemicals For Type, the Middle East and Africa Pharmaceutical Excipients Market is segmented into Glycols, Povidones, Mineral Hydrocarbons, and Other Petrochemicals. The Glycols segment is projected to expand at a CAGR of 4.9% during 2026 - 2034.
• By Inorganic Chemicals For Type, the Middle East and Africa Pharmaceutical Excipients Market is segmented into Magnesium and Calcium Carbonate, Calcium and Aluminum Phosphate, Silicon Dioxide, Titanium Dioxide, and Other Inorganic Chemicals. The Calcium and Aluminum Phosphate segment is projected to expand at a CAGR of 6.5% during 2026 - 2034.
• By Clinical Indication, the Middle East and Africa Pharmaceutical Excipients Market is segmented into Cancer, Metabolic, Infectious Disease, Dental, Ophthalmic, Cardiovascular, and Other Clinical Indications. The Cancer segment is projected to expand at a CAGR of 5.9% during 2026 - 2034.
• By Functionality, the Middle East and Africa Pharmaceutical Excipients Market is segmented into Coloring Agents and Coating Agents, Sweetner and Flavoring Agents, Suspending and Viscosity Agents, Preservative and Controlled Release, Antioxidant and Oil, Tablet Filler and Diluent, Binder and Compression and Granulating Agents, Emulsifiers, Surfactants, and Others. The Tablet Filler and Diluent segment is projected to expand at a CAGR of 4.9% during 2026 - 2034.
• By Surfactants For Functionality, the Middle East and Africa Pharmaceutical Excipients Market is segmented into Polyoxyethylene Hydrogenated Castor Oil, Polysorbates, Sodium Dodecyl Sulfate, and Other Surfactants. The Polysorbates segment is projected to expand at a CAGR of 6.2% during 2026 - 2034.
• By Application, the Middle East and Africa Pharmaceutical Excipients Market is segmented into Oral, Injectable, Topical, and Others. The Oral segment is projected to expand at a CAGR of 5.3% during 2026 - 2034.
• By Oral For Application, the Middle East and Africa Pharmaceutical Excipients Market is segmented into Tablet, Capsule, Liquid, and Others. The Tablet segment is projected to expand at a CAGR of 5.8% during 2026 - 2034.
• By Capsule For Oral, the Middle East and Africa Pharmaceutical Excipients Market is segmented into Hard Gel and Soft Gel. The Hard Gel segment is projected to expand at a CAGR of 5.4% during 2026 - 2034.
• By End User, the Middle East and Africa Pharmaceutical Excipients Market is segmented into Pharma Industries, Biopharma Industries, Animal Health, and Other End User. The Pharma Industries segment is projected to expand at a CAGR of 5.3% during 2026 - 2034.

By country, the Middle East and Africa Pharmaceutical Excipients Market is categorized into Saudi Arabia, South Africa, the United Arab Emirates, and the Rest of Middle East and Africa. Saudi Arabia is projected to expand at a CAGR of 5.5% during 2026 - 2034.

Key players operating in the Pharmaceutical Excipients Market are BASF SE, JRS PHARMA GmbH & Co KG, Roquette Freres SA, Avantor Inc, Archer-Daniels-Midland Co, Evonik Industries AG, Merck KGaA, The Dow Chemical Co, The Lubrizol Corp, Ashland Inc, and MEGGLE GmbH & Co KG, among others.

• In October 2024, Evonik expanded its EUDRACAP portfolio with a new functional, ready-to-fill capsule that enables the delivery of sensitive active ingredients to the ileo-colonic region. EUDRACAP colon has been designed to meet the high customer need for a capsule that can deliver sensitive active ingredients, such as live biotherapeutic products (LBPs) to treat or prevent a wide range of diseases, to the ileo-colonic region. It is currently available in technical grade with a GMP-grade product in development.
• In September 2024, Evonik officially opened a new facility for drying aqueous dispersions of EUDRAGIT polymers at its site in Darmstadt. The new double-digit million-euro excipient manufacturing facility enables Evonik to meet the increasing demand from pharmaceutical customers for oral drug delivery solutions. By expanding production capacities, Evonik is improving supply security and shortening delivery times for EUDRAGIT polymers. The new plant also operates using green electricity and steam generated from local waste incineration, saving more than 1,000 CO2 equivalents per year.